Procept BioRobotics Sets 2026 Revenue Targets Following Hydros Pricing Update
Procept BioRobotics projects 2026 revenue between $390M and $410M, supported by a $450K-$460K pricing strategy for its Hydros system and a 65% gross margin.
Alpha Score of 47 reflects weak overall profile with moderate momentum, poor value, moderate quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.
Alpha Score of 52 reflects moderate overall profile with poor momentum, strong value, strong quality, weak sentiment.
HASBRO, INC. currently screens as unscored on AlphaScala's scoring model.
Alpha Score of 56 reflects moderate overall profile with weak momentum, strong value, moderate quality, weak sentiment.
Procept BioRobotics has established a clear revenue trajectory for 2026, projecting total revenue between $390 million and $410 million. This guidance follows a strategic update regarding the pricing of its Hydros system, which the company now expects to command between $450,000 and $460,000 for the remainder of the year. The firm reported $83.1 million in revenue for the first quarter of 2026, supported by a gross margin of 65 percent.
Revenue Scaling and Hydros Pricing Strategy
The company is positioning its Hydros platform as the primary driver for its mid-term growth objectives. By anchoring the system price within the $450,000 to $460,000 range, Procept aims to balance market penetration with the capital intensity required for its specialized surgical robotics. The 65 percent gross margin achieved in the first quarter serves as a baseline for the company as it scales production and expands its installed base. Maintaining this margin profile while managing the costs associated with the Hydros rollout remains a central component of the firm's path toward sustained EBITDA profitability.
Operational Expansion and Market Reach
Beyond the domestic pricing structure, Procept is focusing on international growth to support its long-term revenue targets. The recent launch in the United Kingdom represents a critical step in diversifying its geographic footprint. This expansion is designed to mitigate reliance on any single market and provide a broader base for system placements. The company's ability to replicate its domestic operational success in new regulatory environments will be a primary indicator of its capacity to meet the upper end of its 2026 revenue projections.
AlphaScala Data and Market Context
Investors monitoring the broader stock market analysis often look for companies that demonstrate a clear link between hardware pricing power and margin expansion. While Procept is currently focused on the medical technology sector, its performance metrics are frequently compared against other growth-oriented firms. For context, our current AlphaScala data shows varied sentiment across other sectors, with AS stock page holding a score of 47, NDAQ stock page at 52, and T stock page at 56. These scores reflect the mixed market conditions currently impacting consumer, financial, and communication services equities.
Procept's next major marker will be the execution of its international sales strategy and the subsequent quarterly reporting of system placement volumes. The company must demonstrate that the current pricing for Hydros does not create friction in the adoption cycle as it moves deeper into the 2026 fiscal year. Any deviation from the projected gross margin or a slowdown in the pace of new system installations will be the primary factors that investors use to evaluate the feasibility of the $390 million to $410 million revenue target.
AI-drafted from named sources and checked against AlphaScala publishing rules before release. Direct quotes must match source text, low-information tables are removed, and thinner or higher-risk stories can be held for manual review.